Free Trial
→ The SpaceX supplier that shipped 5 billion chips to Starlink (From Weiss Ratings) (Ad)tc pixel Free BTTX Stock Alerts

Better Therapeutics (BTTX) Competitors

Better Therapeutics logo
Compare

BTTX vs. UPHL, ACONW, AONC, DHACW, and LFMDP

Should you buy Better Therapeutics stock or one of its competitors? MarketBeat compares Better Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Better Therapeutics include UpHealth (UPHL), Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), and LifeMD (LFMDP). These companies are all part of the "healthcare" industry.

How does Better Therapeutics compare to UpHealth?

Better Therapeutics (NASDAQ:BTTX) and UpHealth (NYSE:UPHL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

34.0% of Better Therapeutics shares are held by institutional investors. Comparatively, 56.1% of UpHealth shares are held by institutional investors. 51.4% of Better Therapeutics shares are held by company insiders. Comparatively, 34.2% of UpHealth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled UpHealth'saverage media sentiment score.

Company Overall Sentiment
Better Therapeutics Neutral
UpHealth Neutral

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
UpHealth N/A N/A N/A

Better Therapeutics has higher earnings, but lower revenue than UpHealth. Better Therapeutics is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.78N/A
UpHealth$130M0.00-$56.42M$1.470.00

Better Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, UpHealth has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Summary

UpHealth beats Better Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Better Therapeutics compare to Aclarion?

Aclarion (NASDAQ:ACONW) and Better Therapeutics (NASDAQ:BTTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

34.0% of Better Therapeutics shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aclarion has higher revenue and earnings than Better Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclarion$77.88KN/AN/AN/AN/A
Better TherapeuticsN/AN/A-$39.76M-$0.78N/A

In the previous week, Aclarion's average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score.

Company Overall Sentiment
Aclarion Neutral
Better Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
AclarionN/A N/A N/A
Better Therapeutics N/A N/A N/A

Summary

Better Therapeutics beats Aclarion on 2 of the 3 factors compared between the two stocks.

How does Better Therapeutics compare to American Oncology Network?

Better Therapeutics (NASDAQ:BTTX) and American Oncology Network (NASDAQ:AONC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

American Oncology Network has higher revenue and earnings than Better Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.78N/A
American Oncology Network$1.34BN/AN/AN/AN/A

In the previous week, American Oncology Network had 2 more articles in the media than Better Therapeutics. MarketBeat recorded 2 mentions for American Oncology Network and 0 mentions for Better Therapeutics. Better Therapeutics' average media sentiment score of 0.00 beat American Oncology Network's score of -0.90 indicating that Better Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Better Therapeutics Neutral
American Oncology Network Negative

34.0% of Better Therapeutics shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
American Oncology Network N/A N/A N/A

Summary

Better Therapeutics beats American Oncology Network on 3 of the 5 factors compared between the two stocks.

How does Better Therapeutics compare to Digital Health Acquisition?

Digital Health Acquisition (NASDAQ:DHACW) and Better Therapeutics (NASDAQ:BTTX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Company Net Margins Return on Equity Return on Assets
Digital Health AcquisitionN/A N/A N/A
Better Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Digital Health AcquisitionN/AN/AN/AN/AN/A
Better TherapeuticsN/AN/A-$39.76M-$0.78N/A

In the previous week, Digital Health Acquisition's average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score.

Company Overall Sentiment
Digital Health Acquisition Neutral
Better Therapeutics Neutral

34.0% of Better Therapeutics shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Better Therapeutics beats Digital Health Acquisition on 2 of the 2 factors compared between the two stocks.

How does Better Therapeutics compare to LifeMD?

LifeMD (NASDAQ:LFMDP) and Better Therapeutics (NASDAQ:BTTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

In the previous week, LifeMD had 1 more articles in the media than Better Therapeutics. MarketBeat recorded 1 mentions for LifeMD and 0 mentions for Better Therapeutics. LifeMD's average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score.

Company Overall Sentiment
LifeMD Neutral
Better Therapeutics Neutral

34.0% of Better Therapeutics shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

LifeMD has higher revenue and earnings than Better Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LifeMD$193.33MN/AN/AN/AN/A
Better TherapeuticsN/AN/A-$39.76M-$0.78N/A

Company Net Margins Return on Equity Return on Assets
LifeMDN/A N/A N/A
Better Therapeutics N/A N/A N/A

Summary

LifeMD and Better Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

Get Better Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BTTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BTTX vs. The Competition

Export
MetricBetter TherapeuticsHealth services IndustryMedical SectorNASDAQ Exchange
Market Cap$4K$1.24M$6.46B$12.34B
Dividend YieldN/AN/A2.76%5.28%
P/E Ratio0.00N/A21.2225.66
Price / SalesN/A0.00562.2886.31
Price / CashN/AN/A43.4956.67
Price / BookN/A0.0010.317.14
Net Income-$39.76M-$56.42M$3.57B$335.98M

Better Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BTTX
Better Therapeutics
N/AN/AN/AN/A$4KN/AN/A40
UPHL
UpHealth
N/A$0.00
-50.0%		N/A-66.7%$2K$130MN/A1,750
ACONW
Aclarion
N/A$0.03
-20.7%		N/A+4.7%$0.00$77.88KN/A7
AONC
American Oncology Network
N/A$12.00
+20.0%		N/A+95.1%$0.00$1.34BN/A1,520
DHACW
Digital Health Acquisition
N/A$0.03
-34.7%		N/AN/A$0.00N/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BTTX) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel